A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)
Status:
Completed
Trial end date:
2019-06-18
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to
etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.